Results 121 to 130 of about 61,463 (315)
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Molecular Oncology, EarlyView.Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy +10 more
wiley +1 more source
Quantum surveillance and 'shared secrets'. A biometric step too far? CEPS Liberty and Security in Europe, July 2010 [PDF]
, 2010 It is no longer sensible to regard biometrics as having neutral socio-economic, legal and political impacts. Newer generation biometrics are fluid and include behavioural and emotional data that can be combined with other data.
Lodge, Juliet.
core
Supporting Data for Internal Structure of Methylcellulose Fibrils
, 2018 Data files used to generate all figures in the manuscript "Internal Structure of Methylcellulose Fibrils" and its supplementary information.The collection of this data was supported primarily by the National Science Foundation through University of ...
Coughlin, McKenzie L +8 more
core +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Red Lodge Clay Center postcard
, 2020 Red Lodge Clay Center Workshop at BSC. March 23 & 24, 2020. [ArtsQuest 2020 was CANCELLED in response to the COVID-19 (coronavirus) pandemic.
Red Lodge Clay Center
core
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source